SEBASTIAN SOLE

Director Médico en Clínica IRAM // Profesor Titular en Universidad Diego Portales

[Evan Thomas MD/PhD @EvanThomas84]

1/Big week for Renaissance: LDRT-MIND just cleared IRB review and approval.

So I can finally talk about what we're doing, which is treating Alzheimer's disease with a new style of low dose radiotherapy.

🧵

[Yüksel Ürün @DrYukselUrun]

In ARTO, adding SBRT-MDT to abiraterone + ADT improved OS in oligo-mCRPC.
@TheLancetOncol @OncoAlert @APCCC_Lugano @BarbaraJereczek @ChadTangMD @OpenMedicineHQ

[Tyler Seibert MD PhD @TylerSbrt]

🚨Evidence for SBRT/SABR to metastases continues to build. #ARTO phase II RCT now with OS benefit in analysis of secondary endpoint. Newly detected mCRPC #ProstateCancer with 1-3 mets.

@urotoday @OncoAlert @PCF_Science @DrSpratticus @ChadTangMD @VedangMurthy @piet_ost

[Pietro Garlatti @PietroGarlatti]

Proud to share that ARTO trial long-term results are out in @TheLancetOncol! 📄✨
​In oligometCRPC, adding SBRT to abi+ADT significantly improves Overall Survival (HR 0.55, p=0.021). PFS 🎯 44 vs 17m!
@GiulioFrancoli1 @dicataldovanes1 @NiccolBertini2 @MicheleAquilano

[Giulio Francolini @GiulioFrancoli1]

Excited to share the results of the #ARTO trial. After a median f-up of 53 months, Adding SBRT to abiraterone + ADT significantly improved overall survival (HR 0.55). @dicataldovanes1 @BarbaraJereczek @Ric_Campi @ChadTangMD @TheLancetOncol @ESTRO_RT
https://t.co/SpNaZHIByX

[Drew Moghanaki @DrewMoghanaki]

🥇 And the award goes to a surgeon willing to lead a randomized trial of radiotherapy versus surgery (prostate cancer) that showed no difference in efficacy, and yet better quality of life with radiotherapy.

[Dr. Andrew Loblaw @DrAndrewLoblaw]

In comparison, what’s the relapse rate after radical Nephrectomy?

What say you Open Evidence…?

Maybe time for an RCT @_ShankarSiva ?

[Advances, an ASTRO Journal @Advances_ASTRO]

📌 Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases 🧠

🔗 https://t.co/zLFWzoaKKY
@ASTRO_org @EJVaios @PeterFecci
@MuzamilArshad18

🔹1383 pts
🔸 large, multi-institutional cohort
🔹 Patients diagnosed with LR were diagnosed sooner after SRS than RN (5.8 vs 8.3 months)
🔸 Local recurrence was associated with significantly worse OS than radionecrosis (15.2 vs 40.4 months)
🔹 Patients symptomatic from either LR or RN presented earlier after SRS than asymptomatic patients and had worse OS
🔸 On binomial logistic regression, RN was associated with single fraction SRS (odds ratio [OR] = 0.38, P = 0.012), receipt of immunotherapy after SRS (OR = 0.32, P < 0.014), and a longer interval from SRS (OR = 0.94, P = 0.028).

[PDBrown @PDBrownOnc]

ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial?
- Upfront RT ↑↑ brain control, no benefit PFS, OS
- Selection criteria high risk (e.g. larger size) for upfront RT is key
https://t.co/1CM31nbxeL

[Dr. Nina Niu Sanford @NiuSanford]

MIRACLE-2: RT to primary/mets -&gt; chemo + tislelizumab in MSS unresectable met rectal ca (N=50): 68% ORR &amp; median OS 23 mo.

Early, single-arm data, but ~1 in 5 pts reached NED.

Suggests RT + systemic + PD1 blockade could overcome immune resistance in MSS mCRC. #ASCO26 @OncoAlert

[Icro Meattini @Icro_Meattini]

Education - Metastatic #BreastCancer

Stereotactic Body #Radiotherapy for Oligometastatic and Oligoprogressive Hormone Receptor-Positive Breast Cancer: When and Why?

Steven J. Chmura #ASCO26

The story is not over @OncoAlert #OncoAlert

[Dr. Nina Niu Sanford @NiuSanford]

Neo-CRAG: Ph3 RCT (n=620, gastric/GEJ) - adding neoadj chemoRT to peri-op XELOX improved OS (68 v 38 mo).

Limitation=non-FLOT, BUT still relevant IMO b/c:

1) DFS/OS benefit substantial.
2) Improvements in pCR, downstg, LRR supports plausible RT effect on OS. #ASCO26 @OncoAlert

[Daniel E Spratt @DrSpratticus]

#APCCC26 @APCCC_Lugano No one better to debate than @piet_ost

Is early SRT "equivalent" to adjuvant RT in high risk/locally advanced disease? Statistically, absolutely not if you believe the RADICALS-RT data.

[Shankar Siva @_ShankarSiva]

New @EurUrol! Pooled trials @PeterMacCC / @UTMDAnderson shows adding Pembrolizumab to MDT for oligometastatic #kidneycancer ⬆️ PFS (28 vs 17 mo; HR 0.57), esp. after prior therapy - https://t.co/lAR0L3WwsE - Correlative data confirm MDT+ICI-evoked immune activation #Kcsm #RadOnc

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Long-term survival for patients with newly-diagnosed metastatic cancer has more than doubled ⏫in the past 40 years.

However, not all patients live longer.

https://t.co/zNg546hKcc
https://t.co/X6wTFytYPL

Work via @JCOOP_ASCO from team at @UHhospitals @CWRUSOM @MayoClinic

[Daniel E Spratt @DrSpratticus]

#APCCC26 Jochin Walz crushes his talk and makes the strong case why waiting until imaging is positive after RP is inappropriate and non-evidence based. Early is better!

[José Máximo Barros, MD 🇦🇷 @barrosonco]

Congreso @SochiraCl
Turno de @SEBASOLE y el
Rol de la RT en el escenario metastasico NSCLC
@hletelier @DrewMoghanaki

[José Máximo Barros, MD 🇦🇷 @barrosonco]

@SEBASOLE
@SochiraCl #XIXCongreso
#OMD #NSCLC

[Evan Thomas MD/PhD @EvanThomas84]

I am thrilled to announce that Renaissance Institute completed the initial phase of its first course of LDRT for an #Alzheimers patient today.

The patient began the treatment course with a MOCA of 15, complete anosmia & ageusia, and A&Ox1.

By the end of Renaissance-modified treatment fractionation, the patient had recovered their sense of taste, was A&Ox4, able to remember my staff’s names, and MOCA improved to 19.

We look forward to opening this new & innovative fractionation scheme in the upcoming LDRT-MIND trial.

#radonc #neurology #dementia

[Alex Hotca, MD @alexhotca]

Interesting that a review on TNT for LARC- w/ extensive discussion of RT toxicity &amp; RT omission - has 0 rad onc authors, cites bowel tox data from 2005, and mischaracterizes PROSPECT data: no better QoL with chemo as they state, but different toxicity profile and no diff in HRQoL